InflaRx (IFRX) director discloses sizeable share and option stakes
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
InflaRx N.V. director Nicolas Fulpius has filed an initial ownership report showing direct holdings of ordinary shares and stock options. He directly owns 490,052 ordinary shares. He also holds several stock option awards over ordinary shares with exercise prices between 1.17 and 2.41 per share and expiration dates running from late 2027 through early 2036. Footnotes state that most earlier option grants are already fully vested and exercisable, while an option granted on January 6, 2026 will vest in four equal quarterly installments of 11,250 shares, subject to continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
9 transactions reported
Mixed
9 txns
Insider
Fulpius Nicolas
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 34,464 shares (Direct);
Ordinary Shares — 490,052 shares (Direct)
Footnotes (1)
- This option was granted on December 13, 2017 and is fully vested and exercisable as of the date hereof. This option was granted on January 4, 2021 and is fully vested and exercisable as of the date hereof. This option was granted on July 2, 2021 and is fully vested and exercisable as of the date hereof. This option was granted on January 12, 2022 and is fully vested and exercisable as of the date hereof. This option was granted on January 24, 2023 and is fully vested and exercisable as of the date hereof. This option was granted on January 5, 2024 and is fully vested and exercisable as of the date hereof. This option was granted on January 3, 2025 and is fully vested and exercisable as of the date hereof. This option was granted on January 6, 2026 and will vest and become exercisable in four equal installments of 11,250 shares on each quarterly anniversary of such grant date, subject to continued service through such dates.
FAQ
What does InflaRx (IFRX) director Nicolas Fulpius report owning on this Form 3?
Nicolas Fulpius reports direct ownership of 490,052 InflaRx ordinary shares, plus multiple stock option awards over additional ordinary shares. These options provide future rights to buy shares at fixed exercise prices, subject to their vesting schedules and expiration dates detailed in the filing.
What stock options does Nicolas Fulpius hold in InflaRx (IFRX)?
He holds several stock options over InflaRx ordinary shares, with exercise prices ranging from 1.17 to 2.41 per share. The options have staggered expiration dates between 2027 and 2036, providing long-dated rights to acquire additional equity if exercised.
Are Nicolas Fulpius’s InflaRx stock options vested and exercisable?
Footnotes state options granted in 2017, 2021, 2022, 2023, 2024, and 2025 are fully vested and exercisable. An option granted on January 6, 2026 will vest in four equal quarterly installments, subject to continued board service.
How does the January 6, 2026 InflaRx option for Nicolas Fulpius vest?
The January 6, 2026 option will vest and become exercisable in four equal installments of 11,250 shares on each quarterly anniversary of the grant date. Vesting is conditioned on continued service through those quarterly vesting dates, according to the footnote disclosure.